Replimune

Image of a neon sign with the word no lit up next to an unlit yes
Biotech

FDA rejects another ultrarare disease prospect

The biotech’s investigational product is designed to treat an extraordinarily rare genetic metabolic disorder that impacts fewer than 1,000 Americans.
Gabrielle Masson Sep 8, 2025 10:59am
FDA

FDA plans real-time release of drug rejection letters

Sep 4, 2025 1:45pm
dominoes fall series fail

Krystal discontinues melanoma study after FDA's Replimune rebuff

Aug 21, 2025 10:50am
Image of a neon sign with the word no lit up next to an unlit yes

Replimune's request for melanoma approval rejected by FDA

Jul 22, 2025 8:45am
Photo of a parachutes opened with a dark blue sky in the background

John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders

Mar 29, 2024 9:30am
end of the road road block shut down closed blocked

Replimune shares halve as skin cancer drug fails phase 2

Dec 5, 2023 10:35am